Aripiprazole (trade names include Abilify, Aripiprex, Aristada, Abilify Discmelt, Arip-MT, Arpizol, Abilify Maintena, Asprito, Azymol, Ilimit, Irazem, Zolerip) is an atypical antipsychotic. This medication is indicated for the treatment of schizophrenia and bipolar disorder (manic-depressive illness). Aripiprazole is also used in adjunctive treatment of depression, major depressive disorder, schizoaffective disorder, irritability associated with autism or autistic disorder, tic disorders, Tourette's disorder, borderline personality disorder, post traumatic stress disorder, obsessive-compulsive disorder, agitated state, agitation associated with schizophrenia or bipolar mania, special considerations in treating pediatric schizophrenia, bipolar 1 disorder, irritability associated with autistic disorder, and other mental conditions. Aripiprazole is also in research studies for counter-therapeutic treatment for methamphetamine dependency. It works by affecting certain substances in the brain.
How and where to order Aripiprazole (Abilify) tablets online:
|Prices:||from $0.49 per pill
|Discount:||10% coupon: DFHDCC
|Forms:|| 5 mg, 10 mg, 15 mg, 20 mg, 30 mg tablets or capsules
|Type:||Aripiprazole brand, Abilify generic
|Payment:||Visa, MasterCard, AmEx, eCheck (ACH), Bitcoin
|Delivery:||Regular and express mail service
|Shipping:||Worldwide, including USA, UK, Europe, Canada, Australia
Lithium Carbonate (Lithobid)
Pharmacological and medical categories:
Add-on treatment medications
N - Nervous system
N05 - Psycholeptics
N05A - Antipsychotics
N05AX - Other antipsychotics
N05AX12 - Aripiprazole
Schizophrenia, schizotypal and delusional disorders - F20-F29
Schizoaffective disorders - F25
Bipolar disorder, single manic episode - F30
Bipolar disorder (bipolar affective disorder) - F31
Major depressive disorder, single episode - F32
Major depressive disorder, recurrent - F33
Obsessive-compulsive disorder - F42
Reaction to severe stress, and adjustment disorders - F43
Post-traumatic stress disorder (PTSD) - F43.1
Specific personality disorders - F60
Borderline personality disorder - F60.3
Pervasive developmental disorders - F84
Tic disorder - F95
Tourette's disorder - F95.2
Autistic disorder - F84.0
Symptoms and signs involving emotional state - R45
Restlessness and agitation - R45.1
Irritability and anger - R45.4
Indications and usage:
Abilify (Aripiprazole) is an atypical antipsychotic. The oral formulations are indicated for:
Acute treatment of manic and mixed episodes associated with bipolar I.
Adjunctive treatment of major depressive disorder.
Irritability associated with autistic disorder.
Treatment of Tourette's disorder.
The injection is indicated for agitation associated with schizophrenia or bipolar mania.
Dosage and administration:
Testing: Prior to or when initiating Truvada test for hepatitis B virus infection. Prior to initiation and during use of Truvada, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all individuals. In individuals with chronic kidney disease, also assess serum phosphorus.
HIV-1 Screening: Screen all individuals for HIV-1 infection immediately prior to initiating Truvada for HIV-1 PrEP and at least once every 3 months while taking this medication, and upon diagnosis of any other sexually transmitted infections (STIs).
Treatment of HIV-1 Infection
Recommended dosage in adultsand pediatric patients weighing at least 35 kg: One Truvada tablet (containing 200 mg of FTCand 300 mg of TDF) once daily taken orally with or without food.
Recommended dosage in pediatric patients weighing at least 17 kg: One Truvada low-strength tablet (100 mg / 150 mg, 133 mg / 200 mg, or 167 mg / 250 mg based on body weight) once daily taken orally with or without food.
Recommended dosage in renally impaired HIV-1 infected adult patients:
- Creatinine clearance (CrCl) 30?49 mL/min: 1 tablet every 48 hours.
- CrCl below 30 mL/min or hemodialysis: Truvada is not recommended.
HIV-1 Pre-Exposure Prophylaxis (PrEP)
Recommended dosage in HIV-1 uninfected adultsand adolescents weighing at least 35 kg: One Truvada tablet (containing 200 mg of FTC and 300 mg of TDF) once daily taken orally with or without food.
Recommended dosage in renally impaired HIV-uninfected individuals: Truvada is not recommended in HIV-uninfected individuals if CrCl is below 60 mL/min.
Dosage forms and strengths:
Oral formulations of Aripiprazole (Abilify): administer once daily without regard to meals.
IM injection: wait at least 2 hours between doses. Maximum daily dose 30 mg.
Known CYP2D6 poor metabolizers: half of the usual dose.
No specific information is available on the treatment of overdose with Abilify (Aripiprazole). An electrocardiogram should be obtained in case of overdosage and if QT interval prolongation is present, cardiac monitoring should be instituted. Otherwise, management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers.
Charcoal: In the event of an overdose of Abilify, an early charcoal administration may be useful in partially preventing the absorption of aripiprazole. Administration of 50 g of activated charcoal, one hour after a single 15mgoral dose of Abilify, decreased the mean AUCand Cmaxof aripiprazole by 50%.
Hemodialysis: Although there is no information on the effect of hemodialysis in treating an overdose with this drug, hemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.
Known hypersensitivity to Aripiprazole (Abilify).
Warnings and precautions:
Cerebrovascular adverse reactions in elderly patients with dementia-related psychosis: increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack, including fatalities).
Neuroleptic malignant syndrome: manage with immediate discontinuation and close monitoring.
Tardive dyskinesia: discontinue if clinically appropriate.
Metabolic changes: atypical antipsychotic drugs have been associatedwith metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and body weight gain.
Hyperglycemia/diabetes mellitus: monitor glucose regularly inpatients with and at risk for diabetes.
Dyslipidemia: undesirable alterations in lipid levels have beenobserved in patients treated with atypical antipsychotics.
Weight gain: weight gain has been observed with atypical antipsychotic use. Monitor weight.
Pathological gambling and other compulsive behaviors: consider dose reduction or discontinuation.
Orthostatic hypotension: monitor heart rate and blood pressure and warnpatients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope.
Leukopenia, neutropenia, and agranulocytosis: have been reported withantipsychotics including Abilify. Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy anddiscontinuation of Aripiprazole should be considered at the first sign of aclinically significant decline in WBC in the absence of other causative factors.
Seizures/convulsions: use cautiously in patients with a history of seizuresor with conditions that lower the seizure threshold.
Potential for cognitive and motor impairment: use caution whenoperating machinery.
Suicide: the possibility of a suicide attempt is inherent in schizophrenia and bipolar disorder. Closely supervise high-risk patients.
Side effects, adverse reactions:
Commonly observed adverse reactions (incidence >= 5% and at least twice that for placebo) of aripiprazole were:
Adult patients with schizophrenia: akathisia.
Pediatric patients (13 to 17 years) with schizophrenia: extrapyramidal disorder, somnolence, and tremor.
Adult patients (monotherapy) with bipolar mania: akathisia, sedation, restlessness, tremor, and extrapyramidal disorder.
Adult patients (adjunctive therapy with lithium or valproate) with bipolar mania: akathisia, insomnia, and extrapyramidal disorder.
Pediatric patients (10 to 17 years) with bipolar mania: somnolence,extrapyramidal disorder, fatigue, nausea, akathisia, blurred vision, salivary hypersecretion, and dizziness.
Adult patients with major depressive disorder (adjunctive treatment to antidepressant therapy): akathisia, restlessness, insomnia, constipation, fatigue, and blurred vision.
Pediatric patients (6 to 17 years) with autistic disorder: sedation, fatigue,vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite, salivary hypersecretion, extrapyramidal disorder, and lethargy.
Pediatric patients (6 to 18 years) with Tourette's disorder: sedation, somnolence, nausea, headache, nasopharyngitis, fatigue, increased appetite.
Adult patients with agitation associated with schizophrenia or bipolar mania: nausea.
To report suspected adverse reactions, contact Otsuka Pharmaceutical, Bristol-Myers Squibb companies or your local FDA.
Known CYP2D6 poor metabolizers: administer half of usual dose.
Known CYP2D6 poor metabolizers and strong CYP3A4 inhibitors: administer a quarter of usual dose.
Strong CYP2D6 or CYP3A4 inhibitors: administer half of usual dose.
Strong CYP2D6 and CYP3A4 inhibitors: administer a quarter of usual dose.
Strong CYP3A4 inducers: double usual dose over 1 to 2 weeks.
Use in specific populations:
Pregnancy: Aripiprazole (Abilify) may cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure.
B3 - Australia
C - United States (Risk cannot be ruled out)
Salts and other forms:
Synonyms, international and chemical names:
Brands, generics, trade names:
Abilify - Bristol-Myers Squibb, Otsuka Pharmaceutical
Abilify Discmelt - Bristol-Myers Squibb
Abilify Maintena - Bristol-Myers Squibb, Otsuka Pharmaceutical
Abilify Mycite - Bristol-Myers Squibb, Otsuka Pharmaceutical
Aria - Abbott, Intas Pharmaceuticals, Nicholas Piramal, Ranbaxy
Arilex FT - Andromaco Laboratorios
Aripa - Platinum Pharmaceuticals
Aripiprazol - Cinfa Laboratorios, EG Labo, KRKA, Mylan, Pliva, Ratiopharm, Sandoz, Stada, TAD Pharma, Teva
Aripiprazole - Accord Healthcare, Alembic, Apotex, Hetero Drugs, Mylan, Sandoz, Teva, Zentiva, Zydus Pharmaceuticals
Aripiprex - Torrent Pharmaceuticals
Arip-MT - Torrent Pharmaceuticals
Aripra - Ranbaxy
Ariski - Actavis
Aristada - Alkermes
Arpit - Crescent Therapeutics
Arpizol - Sun Pharmaceutical Industries
Arzu - Lupin Pharmaceuticals, Pinnacle CVS
Asprito - Intas Pharmaceuticals
Azymol - Drugtech Laboratorio, Recalcine Laboratorios
Ilimit - Pharma Investi de Chile
Irazem - Roemmers Laboratorios
Pipra-A - Psyco Remedies
Rizotal - Talent Healthcare
Schizopra - Cadila Pharmaceuticals, Cinerea Biotech, Micro Labs
Zolerip - Med Ilac
Here is a list of popular medications containing aripiprazole as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
|Trade name of the drug
||Pharmaceutical forms and doses
||Injectable; Injection; Aripiprazole 7.5 mg / mlSolution; Oral; Aripiprazole 1 mg / mlTablets, Orally Disintegrating; Oral; Aripiprazole 10 mgTablets, Orally Disintegrating; Oral; Aripiprazole 15 mgTablets, Orally Disintegrating; Oral; Aripiprazole 20 mgTablets, Orally Disintegrating; Oral; Aripiprazole 30 mgTablets; Oral; Aripiprazole 2 mgTablets; Oral; Aripiprazole 5 mgTablets; Oral; Aripiprazole 10 mgTablets; Oral; Aripiprazole 15 mgTablets; Oral; Aripiprazole 20 mgTablets; Oral; Aripiprazole 30 mg
||Bristol-Myers SquibbAgencia Lei Va HongDKSHOtsuka PharmaceuticalSteward CrossZuellig Pharma
||Tablets, Orally Disintegrating; Oral; Aripiprazole 10 mgTablets, Orally Disintegrating; Oral; Aripiprazole 15 mg
||Tablets; Oral; Aripiprazole 2 mgTablets; Oral; Aripiprazole 5 mgTablets; Oral; Aripiprazole 10 mgTablets; Oral; Aripiprazole 15 mgTablets; Oral; Aripiprazole 20 mgTablets; Oral; Aripiprazole 30 mg
||Tablets; Oral; Aripiprazole 5 mgTablets; Oral; Aripiprazole 10 mgTablets; Oral; Aripiprazole 15 mgTablets; Oral; Aripiprazole 20 mgTablets; Oral; Aripiprazole 30 mg
||Sun Pharmaceutical IndustriesSin Byu Gyun Trading
||Tablets; Oral; Aripiprazole 10 mgTablets; Oral; Aripiprazole 15 mgTablets; Oral; Aripiprazole 20 mgTablets; Oral; Aripiprazole 30 mg
Aripiprazole main article on Wikipedia: https://en.wikipedia.org/wiki/Aripiprazole
Aripiprazole compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Aripiprazole
Aripiprazole on DrugBank: https://go.drugbank.com/drugs/DB01238
Aripiprazole FAQ on MedlinePlus: https://medlineplus.gov/druginfo/meds/a603012.html
Aripiprazole Injection FAQ on MedlinePlus: https://medlineplus.gov/druginfo/meds/a615048.html
Abilify (Aripiprazole) tablets drug label info on DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo...
Abilify (Aripiprazole) tablets, oral solution, orally disintegrating tablets, injection solution, drug label info on DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup...
Aripiprazole tablets drug label info on DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo...
Aripiprazole containing drugs on Drugs-About.com: https://drugs-about.com/ing/aripiprazole.html
Aripiprazole for sale on Pharma Doctor: https://pharma-doctor.com/aripiprazole.html
Aripiprazole international drug names on Drugs.com: https://www.drugs.com/international/aripiprazole.html
Abilify and Abilify Discmelt (Aripiprazole) tablets, oral solution, orally disintegrating tablets, injection solution official prescribing information and medication guide from the U.S. FDA (Revised August 2016): https://www.accessdata.fda.gov/drugsatfda_docs/label...
Abilify and Abilify Discmelt (Aripiprazole) tablets, oral solution, orally disintegrating tablets, injection solution prescribing information and medication guide from Otsuka Pharmaceutical company (Revised June 2020): https://www.otsuka-us.com/media/static/Abilify-PI.pdf
Abilify (Aripiprazole) 2, 5, 10, 15, 20, 30 mg tablets official website: https://www.abilify.com/
Abilify (Aripiprazole) 5 mg, 10 mg, 15 mg, 30 mg tablets package information leaflet on Medicines.org.uk: https://www.medicines.org.uk/emc/files/pil.7148.pdf
Updated: December 2020
Reviewed: December 2020
Copyright © Centre jeunesse du Bas-Saint-Laurent